Abstract:Glycogen storage disease type VI (GSD-VI; also known as Hers disease, liver phosphorylase deficiency) is caused by mutations in the gene coding for glycogen phosphorylase (PYGL) leading to a defect in the degradation of glycogen. Since there are only about 40 patients described in literature, our knowledge about the course of the disease is limited. In order to evaluate the long-term outcome of patients with GSD-VI, an observational retrospective case study of six patients was performed at the University Children's Hospital Zurich. The introduction of small, frequent meals as well as cornstarch has led to normal growth in all patients and to normalization of liver transaminases in most patients. After starting the dietary regimen, there were no signs of hypoglycemia. However, three of six patients showed persistent elevation of triglycerides. Further, we identified four novel pathogenic PYGL mutations and describe here their highly variable impact on phosphorylase function.Conclusions: After establishing the diagnosis, dietary treatment led to metabolic stability and to prevention of hypoglycemia. Molecular genetics added important information for the understanding of the clinical variability in this disease. While outcome was overall excellent in all patients, half of the patients showed persistent hypertriglyceridemia even after initiating treatment.<table class="a-plus-plus table default-table float-no id-taba"><tbody class="a-plus-plus tbody"><tr class="a-plus-plus row"><td class="a-plus-plus entry nameend-c2 namest-c1">What is Known:• Glycogen storage disease type VI (GSD-VI) is a metabolic disorder causing a defect in glycogen degradation. Dietary treatment normally leads to metabolic stability and prevention of hypoglycemia.• However, our knowledge about the natural course of patients with GSD-VI is limited.</td></tr><tr class="a-plus-plus row"><td class="a-plus-plus entry nameend-c2 namest-c1">What is New:• While outcome was overall excellent in all patients, half of the patients showed persistent hypertriglyceridemia even after initiating treatment.• Molecular genetics added important information for the understanding of the clinical variability in this disease.</td></tr></tbody></table>

Characterization of liver GSD IX γ2 pathophysiology in a novel Phkg2-/- mouse model

Liver Glycogen Phosphorylase Deficiency Leads to Profibrogenic Phenotype in a Murine Model of Glycogen Storage Disease Type VI

Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR‐associated protein 9–Mediated Gene Editing

Natural history study of hepatic glycogen storage disease type IV and comparison to Gbe1ys/ys model

Glycogen storage disease type IX: High variability in clinical phenotype

Pathological features of glycogen storage disease type II highlighted in the knockout mouse model

PHKG2 Mutation Spectrum in Glycogen Storage Disease Type IXc: a Case Report and Review of the Literature

Conditional ablation of glycogen synthase kinase 3 β in postnatal mouse kidney

Glycogen Storage Disorder Type IXb: Exploring Clinical Patterns and Genetic Insights Into a Rare Phosphorylase Kinase B (PHKB)-Associated Case

The Phenotypic and Genetic Spectrum of Glycogen Storage Disease Type VI

Clinical features and PHKG2 gene mutation analysis of 5 Chinese patients with glycogen storage disease Ⅸc

[Splicing abnormalities caused by a novel mutation in the PHKA2 gene in children with glycogen storage disease type IX]

Molecular biology and gene therapy for glycogen storage disease type Ib

Induced Muscle and Liver Absence of Gne in Postnatal Mice Does Not Result in Structural or Functional Muscle Impairment

Mutation in PHKA2 Leading to Childhood Glycogen Storage Disease Type IXa

Glycogen storage disease type VI: clinical course and molecular background

Molecular mechanisms of catalytic inhibition for active site mutations in glucose-6-phosphatase catalytic subunit 1 linked to glycogen storage disease

Genotypic and phenotypic characteristics of 12 chinese children with glycogen storage diseases

Genotypic and phenotypic features of 39 Chinese patients with glycogen storage diseases type I, VI, and IX

Disease-associated programming of cell memory in glycogen storage disorder type 1a

Glycogen storage disease type VI can progress to cirrhosis: ten Chinese patients with GSD VI and a literature review.